Core Viewpoint - The Schall Law Firm is investigating Alto Neuroscience, Inc. for potential violations of securities laws following the announcement that its Phase 2b study of ALTO-100 for major depressive disorder did not meet its primary endpoint, leading to a significant drop in the company's stock price [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether Alto Neuroscience made false or misleading statements or failed to disclose important information to investors [1]. - On October 22, 2024, Alto Neuroscience reported that the Phase 2b study of ALTO-100 did not meet its primary endpoint, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [1]. - Following this announcement, shares of Alto Neuroscience fell by nearly 60% in after-hours trading on the same day [1].
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm